Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J N Ingle

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Gynecologic Oncology|November 1, 1994
Tamoxifen and endometrial cancer: new challenges for an "old" drugJ N Ingle
Cancer|February 1, 1984
Additive hormonal therapy in women with advanced breast cancerJ N Ingle
Cancer|March 8, 2000
Multicultural aspects of breast cancer etiology workshop: concluding commentsJ N Ingle
Oncology (Williston Park, N.Y.)|June 9, 2001
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemopreventionJ N Ingle
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2002
Current status of adjuvant endocrine therapy for breast cancerJ N Ingle
Hematology/Oncology Clinics of North America|December 1, 1989
Principles of therapy in advanced breast cancerJ N Ingle
The New England Journal of Medicine|February 1, 1990
Assessing the risk of recurrence in breast cancerJ N Ingle
Mayo Clinic Proceedings|April 1, 1984
Integration of hormonal agents and chemotherapy for the treatment of women with advanced breast cancerJ N Ingle
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Increased HER2 with U.S. Food and Drug Administration-approved antibodyP C Roche, J N Ingle
Clinical Pharmacology and Therapeutics|July 25, 2014
CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studiesM P Goetz, J N Ingle
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Gynecologic Oncology|November 1, 1994
Tamoxifen and endometrial cancer: new challenges for an "old" drugJ N Ingle
Cancer|February 1, 1984
Additive hormonal therapy in women with advanced breast cancerJ N Ingle
Cancer|March 8, 2000
Multicultural aspects of breast cancer etiology workshop: concluding commentsJ N Ingle
Oncology (Williston Park, N.Y.)|June 9, 2001
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemopreventionJ N Ingle
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2002
Current status of adjuvant endocrine therapy for breast cancerJ N Ingle
Hematology/Oncology Clinics of North America|December 1, 1989
Principles of therapy in advanced breast cancerJ N Ingle
The New England Journal of Medicine|February 1, 1990
Assessing the risk of recurrence in breast cancerJ N Ingle
Mayo Clinic Proceedings|April 1, 1984
Integration of hormonal agents and chemotherapy for the treatment of women with advanced breast cancerJ N Ingle
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Increased HER2 with U.S. Food and Drug Administration-approved antibodyP C Roche, J N Ingle
Clinical Pharmacology and Therapeutics|July 25, 2014
CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studiesM P Goetz, J N Ingle
Pageof 17